Inclusion Criteria:

          1. Male or female aged ≥ 18 years old

          2. One or more metastatic tumors measurable on computed tomography (CT) scan per RECIST
             version 1.1 and screening FDG-PET scan with maximum standardized uptake value (SUV
             max) ≥ 5.5 for at least one lesion consistent with pancreatic cancer.

          3. Karnofsky performance status ≥ 70%

          4. Life expectancy of at least 3 months

          5. Able to understand the information provided to them and to give written institutional
             review board (IRB)-approved informed consent prior to any study activities being
             conducted

          6. A negative pregnancy test (if of child bearing potential)

          7. Acceptable liver function:

               1. Bilirubin ≤ 1.5 times upper limit of normal

               2. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Alkaline
                  phosphatase (ALP) ≤ 2.5 times upper limit of normal (ULN; if liver metastases are
                  present, then ≤ 5 x ULN is allowed)

          8. Acceptable renal function as defined by creatinine ≤1.5x institutional upper limits of
             normal, or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with
             creatinine levels above institutional normal

          9. Acceptable hematologic status:

               1. Granulocyte ≥ 1500 cells/mm3

               2. Platelet count ≥ 100,000 (plt/mm3)

               3. Hemoglobin ≥ 9g/dL

         10. Urinalysis:

             a) No clinically significant abnormalities

         11. Acceptable coagulation status

               1. Prothrombin time within 1.5x of normal limits

               2. Partial thromboplastin time (PTT) within 1.5x of normal limits

         12. For men and women of child-bearing potential, the use of effective contraceptive
             methods during the study

         13. Normal ejection fraction on ECHO or MUGA

        Exclusion Criteria:

          1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction
             within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG

          2. Abnormal ejection fraction on ECHO or MUGA

          3. Active, uncontrolled bacterial, viral, or fungal infections requiring systematic
             therapy

          4. Pregnant or nursing women. NOTE: Women of childbearing potential and men must agree to
             use adequate contraception (hormonal or barrier method of birth control; or
             abstinence) prior to study entry and for the duration of study participation. Should a
             woman become pregnant while participating in this study, she should inform her
             treating physician immediately.

          5. Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy
             within 3 weeks prior to study entry

          6. Major surgery within 4 weeks prior to study entry

          7. Unwillingness or inability to comply with procedures required in this protocol

          8. Known infection with HIV, hepatitis B, or hepatitis C

          9. Serious nonmalignant disease (eg hydro nephrosis, liver failure, or other conditions)
             that could compromise protocol objectives in the opinion of the investigator and/or
             the sponsor

         10. Patients who are currently receiving any other investigational agent

         11. Patients with any evidence of uncontrolled brain metastases or carcinomatosis
             meningitis.

         12. Patients with marked screening prolongation of QT/QTc interval (e.g. repeated
             demonstration of a QTc interval > 480 milliseconds (CTCAE grade 1) using Fredericia's
             QT correction formula.